Showing results (761-770 of 778) with videos related to

Sort By:
Pageof 78
Journal of Clinical Medicine|June 28, 2023
Timing of Lung Transplant Referral in Patients with Severe COVID-19 Lung Injury Supported by ECMOLiran Levy, Ofir Deri, Ella Huszti, et al.
Leukemia|April 18, 2008
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myelomaG Schilling, T Hansen, A Shimoni, et al.
JACC. Cardiovascular Imaging|March 8, 2023
Prognostic Value of Preprocedural LV Global Longitudinal Strain for Post-TAVR-Related Morbidity and Mortality: A Meta-AnalysisNiels A Stens, Odette van Iersel, Max J P Rooijakkers, et al.
Plos Computational Biology|May 15, 2013
Improving breast cancer survival analysis through competition-based multidimensional modelingErhan Bilal, Janusz Dutkowski, Justin Guinney, et al.
Leukemia|May 8, 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysisPhilipp Berning, Norbert Schmitz, Maud Ngoya, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
Transplantation and Cellular Therapy|March 1, 2026
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell LymphomaMarina Gomez-Llobell, Roni Shouval, Samantha Brown, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Pageof 78